Program Overview
In this module, Ryan B. Corcoran, MD PhD, along with Scott Kopetz, MD, PhD, course chair, will highlight current clinical trial data for BRAF and Anti-PD-1 targeted therapeutic options in the colorectal cancer treatment landscape. The expert faculty will provide an in-depth review of novel studies by analyzing study populations, methods and results, as well as providing key takeaways for practice. Ongoing trials, as well future directions of treating colorectal cancer with BRAF and Anti-PD-1 targeted therapies, will be relayed through a prospective lens. This 30-minute module will provide insight into utilizing current clinical trial data in practice to improve outcomes for patients with colorectal cancer.
Target Audience
Community oncologists, oncologists, advanced practitioners, oncology nurses, and other healthcare professionals involved in the care of patients with colorectal cancer
Learning Objective
- Analyze recent clinical trial data of current and emerging treatment options for the management of patients with colorectal cancer
Faculty
Scott Kopetz, MD, PhD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ryan B. Corcoran, MD PhD
Director, Gastrointestinal Cancer Center Program
Scientific Director, Termeer Center for Targeted Therapy
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: |
| Scott Kopetz, MD, PhD
|
Consultant/Advisor: Amal Therapeutics; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer Health; Biocartis; Boehringer Ingelheim International GmbH; Boston Biomedical, Inc.; EMD Serono Inc.; Eli Lilly and Company; Genentech Inc.; Holy Stone Healthcare Co., Ltd.; Karyopharm Therapeutics; MedImmune; Merck & Co., Inc.; Navire Pharma; Novartis Pharmaceuticals Corporation; Pierre Fabre; Roche; Redx Pharma; Symphogen
Research/Grant Support: Amgen Inc.; Array BioPharma; Biocartis; Eli Lilly and Company; EMD Serono Inc.; Genentech, Inc.; Guardant Health; MedImmune; Novartis Pharmaceuticals Corporation; Roche; Sanofi Stock Option: MolecularMatch; Navire Pharma |
| Ryan B. Corcoran, MD PhD | Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Array BioPharma; Asana BioSciences, LLC; Astex Pharmaceuticals; AstraZeneca Pharmaceuticals; Avidity Biosciences; Bristol-Myers Squibb Company; C4 Therapeutics; Chugai Pharma USA, Inc; Elicio Therapeutics Inc.; FogPharma; Fount Therapeutics, LLC; Genentech Inc.; Guardant Health; Ipsen Pharma; Kinnate Biopharma Inc.; Loxo Oncology; Merrimack Pharmaceuticals; Natera; Pfizer Inc.; Novartis Pharmaceuticals Corporation; nRichDx; Qiagen; Revolution Medicines; Roche; Roivant Sciences; Shionogi Inc; Shire; Spectrum Pharmaceuticals; Symphogen; Tango Therapeutics; Taiho Oncology Inc.; Warp Drive Bio, LLC; Zikani Therapeutics
Stock Option: Avidity Biosciences; C4 Therapeutics; Fount Therapeutics, LLC; Kinnate Biopharma Inc.; nRichDx; Revolution Medicines Research/Grant Support: Asana BioSciences, LLC; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Sanofi |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).
Financial Support
This activity has been supported by an independent educational grant from Merck & Co., Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
